JP2007537147A - メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用 - Google Patents
メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用 Download PDFInfo
- Publication number
- JP2007537147A JP2007537147A JP2006547452A JP2006547452A JP2007537147A JP 2007537147 A JP2007537147 A JP 2007537147A JP 2006547452 A JP2006547452 A JP 2006547452A JP 2006547452 A JP2006547452 A JP 2006547452A JP 2007537147 A JP2007537147 A JP 2007537147A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- compound
- unsubstituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(N(*)C(*)(*)**)=O Chemical compound CC(N(*)C(*)(*)**)=O 0.000 description 8
- FKYBFNMJAPHNKT-DUPQHEJVSA-N CC(C)([C@H](C(N)=O)NC(O[C@H](CC[C@]1(C2[C@]3(C)[C@@H](C/C=C(\C)/CO)C3)OC1)[C@H]2C=O)=O)O Chemical compound CC(C)([C@H](C(N)=O)NC(O[C@H](CC[C@]1(C2[C@]3(C)[C@@H](C/C=C(\C)/CO)C3)OC1)[C@H]2C=O)=O)O FKYBFNMJAPHNKT-DUPQHEJVSA-N 0.000 description 1
- ZIIMGBJUPYFMTE-ANPKHJSNSA-N CC(C)([C@H](C(N)=O)NC(O[C@H](CC[C@]1(C2[C@]3(C)[C@@H](CC=C(C)C)CC3)OC1)[C@H]2C=O)=O)O Chemical compound CC(C)([C@H](C(N)=O)NC(O[C@H](CC[C@]1(C2[C@]3(C)[C@@H](CC=C(C)C)CC3)OC1)[C@H]2C=O)=O)O ZIIMGBJUPYFMTE-ANPKHJSNSA-N 0.000 description 1
- QHWFBZYZSVFGSY-GGMIKJKGSA-N CC(C)[C@H](C(N)=O)NC(O[C@H](CC[C@]1(C2[C@]3(C)[C@@H](C[C@H]4OC4(C)C)CC3)OC1)[C@H]2O)=O Chemical compound CC(C)[C@H](C(N)=O)NC(O[C@H](CC[C@]1(C2[C@]3(C)[C@@H](C[C@H]4OC4(C)C)CC3)OC1)[C@H]2O)=O QHWFBZYZSVFGSY-GGMIKJKGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53343103P | 2003-12-29 | 2003-12-29 | |
| PCT/US2004/043586 WO2005066197A2 (en) | 2003-12-29 | 2004-12-29 | Inhibitors of methionine aminopeptidase-2 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007537147A true JP2007537147A (ja) | 2007-12-20 |
| JP2007537147A5 JP2007537147A5 (https=) | 2008-02-07 |
Family
ID=34748901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547452A Pending JP2007537147A (ja) | 2003-12-29 | 2004-12-29 | メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050239878A1 (https=) |
| EP (1) | EP1699812A2 (https=) |
| JP (1) | JP2007537147A (https=) |
| KR (1) | KR20060130077A (https=) |
| CN (1) | CN1902215A (https=) |
| AU (1) | AU2004312512A1 (https=) |
| CA (1) | CA2550873A1 (https=) |
| NO (1) | NO20062812L (https=) |
| WO (1) | WO2005066197A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003230852B2 (en) * | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| AU2003226349B2 (en) * | 2002-04-11 | 2008-01-31 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20070254843A1 (en) * | 2006-04-18 | 2007-11-01 | Praecis Pharmaceuticals Incorporated | Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors |
| WO2008066641A2 (en) * | 2006-11-06 | 2008-06-05 | Praecis Pharmaceuticals Incorporated | Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors |
| EP2170402B1 (en) * | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| US8865746B2 (en) | 2008-07-18 | 2014-10-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| CA2777108A1 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| BR112012016793A2 (pt) | 2010-01-08 | 2018-07-31 | Zafgen Corp | compostos tipo fumagilol e métodos de fazer e usar os mesmos |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| WO2011088055A2 (en) | 2010-01-12 | 2011-07-21 | Zafgen Corporation | Methods and compositions for treating cardiovascular disorders |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| CN103249735B (zh) | 2010-07-22 | 2016-04-06 | 扎夫根股份有限公司 | 三环化合物及其制备和使用方法 |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
| WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
| US9173865B2 (en) | 2010-11-29 | 2015-11-03 | Zafgen, Inc. | Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol |
| US9189078B2 (en) | 2010-12-20 | 2015-11-17 | Apple Inc. | Enhancing keycap legend visibility with optical components |
| MX344238B (es) | 2011-01-26 | 2016-12-07 | Zafgen Inc | Compuestos de tetrazol y métodos para preparar y usar los mismos. |
| EP2683706B1 (en) | 2011-03-08 | 2018-02-21 | Zafgen, Inc. | Oxaspiro [2.5]octane derivatives and analogs |
| EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| CN103764641B (zh) | 2011-05-06 | 2016-10-26 | 扎夫根股份有限公司 | 部分饱和的三环化合物及其制备和使用方法 |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| MX2014008706A (es) | 2012-01-18 | 2015-03-05 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
| JP2015509102A (ja) | 2012-01-18 | 2015-03-26 | ザフゲン，インコーポレイテッド | 三環式スルホン化合物並びにその作製および使用方法 |
| BR112014027808A2 (pt) | 2012-05-07 | 2017-06-27 | Zafgen Inc | sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo |
| MX2014013599A (es) | 2012-05-08 | 2015-05-11 | Zafgen Inc | Tratamiento de la obesidad hipotalamica con inhibidores de metap2. |
| BR112014027981A2 (pt) | 2012-05-09 | 2017-06-27 | Zafgen Inc | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos |
| MX2015005733A (es) | 2012-11-05 | 2016-02-10 | Zafgen Inc | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |
| AU2013337282A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| WO2018148638A1 (en) * | 2017-02-10 | 2018-08-16 | Zafgen, Inc. | Pharmaceutical compositions of metap-2 inhibitors |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0415294A2 (en) * | 1989-08-31 | 1991-03-06 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| WO1998056372A1 (en) * | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| US20020193298A1 (en) * | 2000-11-01 | 2002-12-19 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| WO2003092608A2 (en) * | 2002-05-02 | 2003-11-13 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
| US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| KR0138530B1 (ko) * | 1988-09-01 | 1998-05-15 | 우메모또 요시마사 | 푸마길롤 유도체 |
| US5180738A (en) * | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
| US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| JPH06157344A (ja) * | 1992-02-07 | 1994-06-03 | Childrens Medical Center Corp:The | 血管新生阻害のための医薬製剤及び血管新生阻害方法 |
| EP0602586B1 (en) * | 1992-12-16 | 1997-06-04 | Takeda Chemical Industries, Ltd. | Stable pharmaceutical composition of fumagillol derivatives |
| FR2733498B1 (fr) * | 1995-04-27 | 1997-05-30 | Adir | Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2004
- 2004-12-29 WO PCT/US2004/043586 patent/WO2005066197A2/en not_active Ceased
- 2004-12-29 JP JP2006547452A patent/JP2007537147A/ja active Pending
- 2004-12-29 EP EP04815618A patent/EP1699812A2/en not_active Withdrawn
- 2004-12-29 KR KR1020067012422A patent/KR20060130077A/ko not_active Withdrawn
- 2004-12-29 AU AU2004312512A patent/AU2004312512A1/en not_active Abandoned
- 2004-12-29 CN CNA2004800393912A patent/CN1902215A/zh active Pending
- 2004-12-29 US US11/025,568 patent/US20050239878A1/en not_active Abandoned
- 2004-12-29 CA CA002550873A patent/CA2550873A1/en not_active Abandoned
-
2006
- 2006-06-15 NO NO20062812A patent/NO20062812L/no not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0415294A2 (en) * | 1989-08-31 | 1991-03-06 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| WO1998056372A1 (en) * | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| US20020193298A1 (en) * | 2000-11-01 | 2002-12-19 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| WO2003092608A2 (en) * | 2002-05-02 | 2003-11-13 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1699812A2 (en) | 2006-09-13 |
| AU2004312512A1 (en) | 2005-07-21 |
| CN1902215A (zh) | 2007-01-24 |
| NO20062812L (no) | 2006-07-21 |
| CA2550873A1 (en) | 2005-07-21 |
| WO2005066197A2 (en) | 2005-07-21 |
| US20050239878A1 (en) | 2005-10-27 |
| KR20060130077A (ko) | 2006-12-18 |
| WO2005066197A3 (en) | 2006-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537147A (ja) | メチオニンアミノペプチダーゼ−２のインヒビターおよびその使用 | |
| US7037890B2 (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
| US5290807A (en) | Method for regressing angiogenesis using o-substituted fumagillol derivatives | |
| US5698586A (en) | Angiogenesis inhibitory agent | |
| JP2004531466A (ja) | 血管新生を調節するための治療薬およびその使用方法 | |
| KR100648578B1 (ko) | α-케토아미드 다촉매활성의 프로테아제 억제제 | |
| EP0357061A1 (en) | Angiogenesis inhibitory agent | |
| KR20050009702A (ko) | 메티오닌 아미노펩티다제-2 저해제 및 이의 이용방법 | |
| US7098186B2 (en) | Depsipeptide compound | |
| JP4213339B2 (ja) | 発作を治療するのに有用なアミノ酸誘導体 | |
| US6596715B1 (en) | Protease inhibitors | |
| US6534498B1 (en) | Protease inhibitors | |
| EP1140897A1 (en) | Protease inhibitors | |
| MXPA06007365A (es) | Inhibidores de metionina aminopeptidasa-2 y usos de los mismos | |
| EP1231923A1 (en) | Protease inhibitors | |
| US6583137B1 (en) | Protease inhibitors | |
| EP0372410B1 (en) | Use of heterocyclic amides to inhibit tumor metastasis | |
| CN115974719B (zh) | 化合物、包括所述化合物的药物组合物及其用途 | |
| US20250144109A1 (en) | Compositions for preventing or treating pulmonary arterial hypertension | |
| EP1231922A1 (en) | Protease inhibitors | |
| US20250170137A1 (en) | Compositions for preventing or treating heart failure (HF) | |
| JPH06345644A (ja) | 自己免疫性疾患治療剤 | |
| US7199146B2 (en) | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | |
| KR20050038632A (ko) | 양성 및 악성 종양 질환의 치료를 위한 디스오라졸 및 이의유도체를 함유하는 의약 | |
| WO2022105825A1 (en) | Compounds as pu. 1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071212 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080313 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111011 |